The estimated Net Worth of William Huyett is at least 239 千$ dollars as of 6 November 2020. Mr. Huyett owns over 3,827 units of Cyclerion Therapeutics stock worth over 203,108$ and over the last 7 years he sold CYCN stock worth over 35,906$. In addition, he makes 0$ as Chief Financial Officer at Cyclerion Therapeutics.
William has made over 3 trades of the Cyclerion Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 3,827 units of CYCN stock worth 9,644$ on 6 November 2020.
The largest trade he's ever made was selling 3,922 units of Cyclerion Therapeutics stock on 8 November 2019 worth over 8,040$. On average, William trades about 1,256 units every 40 days since 2018. As of 6 November 2020 he still owns at least 67,590 units of Cyclerion Therapeutics stock.
You can see the complete history of Mr. Huyett stock trades at the bottom of the page.
William Huyett serves as Chief Financial Officer of the Company. He has served as our Chief Financial Officer since we commenced operations as an independent company in April 2019. Prior to joining Cyclerion, Mr. Huyett served as chief operating officer of Ironwood Pharmaceuticals, Inc. from December 2017 to March 2019. Mr. Huyett previously spent 30 years with McKinsey and Company, Inc., in its Washington D.C., Zurich, and Boston offices. During his tenure at McKinsey, Mr. Huyett served clients in the life sciences, industrial and other technology-intensive sectors. He has been a Senior Partner Emeritus at McKinsey since December 2015 and a Senior Partner from July 1998 to December 2015. As a Senior Partner, Mr. Huyett was a leader in the firm’s pharmaceutical and medical products and its strategy and corporate finance practices. He served on McKinsey’s Shareholder’s Council (its board of directors), serving as chair of its Finance Committee. Prior to joining McKinsey, Mr. Huyett held a variety of line management positions in the automation industry with Allen-Bradley (now Rockwell Automation, Inc.). Mr. Huyett is non-executive Chair of the board of directors of the London Stock Exchange-listed Georgia Healthcare Group PLC. He serves on several life science not-for-profit boards, including The Rockefeller University and the Marine Biological Laboratory in Woods Hole. He earned his B.S. in electronics engineering and his M.B.A. from the University of Virginia.
William Huyett is 64, he's been the Chief Financial Officer of Cyclerion Therapeutics since 2019. There are 4 older and 10 younger executives at Cyclerion Therapeutics. The oldest executive at Cyclerion Therapeutics, Inc. is George Conrades, 81, who is the Independent Director.
William's mailing address filed with the SEC is C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE, MA, 02142.
Over the last 6 years, insiders at Cyclerion Therapeutics have traded over 240,273$ worth of Cyclerion Therapeutics stock and bought 4,653,203 units worth 33,009,775$ . The most active insiders traders include Peter M Hecht、Mark G Currie、Terrance Mcguire. On average, Cyclerion Therapeutics executives and independent directors trade stock every 84 days with the average trade being worth of 749,841$. The most recent stock trade was executed by Terrance Mcguire on 9 August 2023, trading 8 units of CYCN stock currently worth 27$.
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Cyclerion Therapeutics executives and other stock owners filed with the SEC include: